PNAS:肠道菌群或有助乙肝病毒清除

2015-02-05 伊文 EurekAlert中文

一项研究发现,定植的肠道微生物群可能在成年小鼠肝脏清除乙肝感染的能力方面起到了一个作用。 尽管成年人获得的乙肝感染的至多95%被自发清除了,新生儿或者儿童期早期暴露在这种病毒中,常常导致慢性感染。为了研究与年龄相关的病毒清除, Ding-Shinn Chen、Hurng-Yi Wang及其同事向不同年龄的小鼠注射了乙肝病毒DNA。成年小鼠在注射后的6周时间里

一项研究发现,定植的肠道微生物群可能在成年小鼠肝脏清除乙肝感染的能力方面起到了一个作用。

尽管成年人获得的乙肝感染的至多95%被自发清除了,新生儿或者儿童期早期暴露在这种病毒中,常常导致慢性感染。为了研究与年龄相关的病毒清除, Ding-Shinn Chen、Hurng-Yi Wang及其同事向不同年龄的小鼠注射了乙肝病毒DNA。成年小鼠在注射后的6周时间里清除了这种感染,但是年轻的小鼠在注射后26周的测试呈阳性。

这组作者还发现,接受抗生素治疗从而杀死了肠道微生物群的小鼠无法迅速清除这种病毒。对缺乏toll样受体4(TLR4)免疫信号传导路径的小鼠的进一步的实验发现,缺乏toll样受体4(TLR4)的小鼠在8周内清除了这种病毒,而无论年龄如何。

这组作者说,这些结果提示,年轻的小鼠肝脏表现出了一种耐受乙肝病毒的toll样受体4(TLR4)依赖型免疫应答,而肠道微生物群的发育与成熟可能引发一种替代的免疫应答,有能力清除这种感染。

原始出处:

Chou HH1, Chien WH2, Wu LL3, Cheng CH1, Chung CH3, Horng JH4, Ni YH5, Tseng HT6, Wu D7, Lu X7, Wang HY8, Chen PJ3, Chen DS9.Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota.Proc Natl Acad Sci U S A. 2015 Feb 2. pii: 201424775. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=195701, encodeId=02bd195e01c1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue May 09 08:10:28 CST 2017, time=2017-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855697, encodeId=5970185569e33, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Sep 06 19:55:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15908, encodeId=b2c9159087b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:42:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392159, encodeId=2efa13921592b, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Sat Feb 07 01:55:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15178, encodeId=b4ca151e8f6, content=有点扯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 18:13:00 CST 2015, time=2015-02-05, status=1, ipAttribution=)]
    2017-05-09 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=195701, encodeId=02bd195e01c1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue May 09 08:10:28 CST 2017, time=2017-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855697, encodeId=5970185569e33, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Sep 06 19:55:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15908, encodeId=b2c9159087b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:42:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392159, encodeId=2efa13921592b, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Sat Feb 07 01:55:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15178, encodeId=b4ca151e8f6, content=有点扯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 18:13:00 CST 2015, time=2015-02-05, status=1, ipAttribution=)]
    2015-09-06 drwjr
  3. [GetPortalCommentsPageByObjectIdResponse(id=195701, encodeId=02bd195e01c1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue May 09 08:10:28 CST 2017, time=2017-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855697, encodeId=5970185569e33, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Sep 06 19:55:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15908, encodeId=b2c9159087b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:42:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392159, encodeId=2efa13921592b, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Sat Feb 07 01:55:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15178, encodeId=b4ca151e8f6, content=有点扯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 18:13:00 CST 2015, time=2015-02-05, status=1, ipAttribution=)]
    2015-02-16 windmilL1989

    已阅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=195701, encodeId=02bd195e01c1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue May 09 08:10:28 CST 2017, time=2017-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855697, encodeId=5970185569e33, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Sep 06 19:55:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15908, encodeId=b2c9159087b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:42:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392159, encodeId=2efa13921592b, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Sat Feb 07 01:55:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15178, encodeId=b4ca151e8f6, content=有点扯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 18:13:00 CST 2015, time=2015-02-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=195701, encodeId=02bd195e01c1, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Tue May 09 08:10:28 CST 2017, time=2017-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855697, encodeId=5970185569e33, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Sun Sep 06 19:55:00 CST 2015, time=2015-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15908, encodeId=b2c9159087b, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:42:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1392159, encodeId=2efa13921592b, content=<a href='/topic/show?id=223081e33b6' target=_blank style='color:#2F92EE;'>#肠道菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81733, encryptionId=223081e33b6, topicName=肠道菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa292500107, createdName=1249897bm37(暂无昵称), createdTime=Sat Feb 07 01:55:00 CST 2015, time=2015-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15178, encodeId=b4ca151e8f6, content=有点扯, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Thu Feb 05 18:13:00 CST 2015, time=2015-02-05, status=1, ipAttribution=)]
    2015-02-05 lovetcm

    有点扯

    0

相关资讯

JCO:曹广文等发现核苷/核苷类似物可改善乙肝病毒相关肝细胞癌患者术后生存

研究要点: 1.旨在研究核苷/核苷类似物治疗对乙肝病毒相关肝细胞癌患者预后的影响。 2.两阶段纵向研究,第一阶段针对非随机干预队列评估NA治疗对接受手术治疗乙肝病毒相关肝细胞癌患者预后情况的影响;第二阶段为随机临床试验,旨在验证第一阶段结果。 3.核苷/核苷类似物治疗可有效恢复患者肝脏功能,降低HBV-HCC复发率并改善术后患者生存。 4.邻近部位肝组织的Ct-HBx表达水平可作为抗病毒治

Hepatology:阿德福韦或引起耐药乙肝病毒准种变化

长期使用核苷类抗病毒药物,会使病人出现耐药而导致病毒反跳或者应答不佳,而耐药病毒的具体演变过程至今仍不清楚。针对这种情况,来自法国巴黎大学的Christophe Rodriguez等人进行了一项研究,研究结果发表在2013年9月的《Hepatology》上。研究发现,对于阿德福韦治疗失败的病人,其治疗过程中准种演变非常复杂且具有个体差异,而拉米夫定能部分抑制耐阿德福韦菌种的适应性。【原文下载】

乙肝病毒再激活的发病率、致病机制和预防

对于要经历化疗的乙肝病毒(HBV)携带者来说,HBV在免疫抑制的肿瘤病人中的重激活是一个临床难题。因为HBV的重激活不仅会造成严重的肝脏损伤,而且会中断治疗恶性肿瘤的化疗方案。 来自意大利贝尔加莫的肿瘤学和血液学中心的M. Mandalà教授对免疫抑制的肿瘤病人中HBV的再激活的发病率,致病机制以及临床处理进行了综述。该综述还评价了主要的预防措施的意义。该综述发表在2013年7月的Criti

Immunity: 科学家发现乙肝病毒免疫新机制

乙型肝炎是中国人群中高发的一类传染型疾病,乙肝会导致肝功能障碍,肝硬化以及肝癌的发生。引起乙肝的是一种B型肝炎病毒(hepatitis B virus, HBV)。 宿主对外援病原体的入侵具有一系列的抵抗机制。对于病毒来说,其携带的DNA或RNA分子能够被细胞内部的各类感受器分子识别(如病毒5' 磷酸化或双链RNA可以被RIG-I (retinoic acid-inducible gene-I)

Cancer Cell:揭秘乙肝病毒诱导肝癌之谜

肝细胞肝癌是少数几种可以直接由病毒(乙肝病毒HBV和丙肝病毒HCV)诱发的恶性肿瘤,目前肝细胞肝癌的首要诱因是HBV。HBV引起肝癌主要机制包括以下几种:(1) 病毒蛋白HBx直接作用于肝细胞,刺激其增殖能力;(2) 长期HBV感染刺激宿主免疫反应,逐渐发生肝脏炎症、肝硬化,最后导致肝癌发生;(3) HBV基因插入宿主基因组中,融合后直接促进肝癌发生。HBV插入融合至宿主基因的学说早在1980

EASL 2014:NUCs与IFN联合序贯治疗提高慢乙肝病毒学应答率

该研究来自中国复旦大学华山医院张文宏教授研究组。该回顾性研究旨在评估核苷类似物与聚乙二醇干扰素(PEG-IFN)序贯联合治疗既往长期NUCs治疗的慢乙肝患者的效果。 既往接受至少两年的NUCs治疗未实现HBeAg转阴或血清学转换的192例慢乙肝患者,接受48周的PEG-IFN序贯联合NUCs治疗或NUCs单药治疗。在上述患者中,83例患者采用联合治疗,109例患者采用NUCs单药治疗。所有患者进一